ALK and neuroblastoma: Thus, as ALK mutations, as well as amplifications [117], are found in NB pathogenesis, this tyrosine kinase is considered to be a major oncogenic driver of the disease and triggered the study of ALK inhibition as a therapeutic option [15,118].